Friday, February 27, 2026

The Daily

A Curated Briefing

Vienna — Partly cloudy, 6°C (feels 3°C)
High 8° · Low 2°
Light winds, dry

Biotech & Pharma

FDA Watch

Five FDA Decisions to Watch This Quarter — Obesity, Rare Disease, and Gene Therapy on the Line

The first quarter of 2026 brings pivotal regulatory moments across metabolic disease and rare disorders. Eli Lilly's oral GLP-1 orforglipron could win approval within weeks thanks to a national priority voucher, potentially cutting Novo Nordisk's oral Wegovy lead to mere days. Disc Medicine's bitopertin faces scrutiny despite promising data for erythropoietic protoporphyria. Ascendis Pharma's once-weekly TransCon CNP challenges BioMarin's achondroplasia monopoly by February's end. Rhythm Pharmaceuticals seeks expansion for Imcivree into hypothalamic obesity—a $1B+ market—while Rocket Pharma aims for redemption with gene therapy Kresladi after manufacturing setbacks. These decisions will reshape competitive landscapes and unlock multi-billion-dollar opportunities.

BioPharma Dive

Regulatory

Orforglipron Could Erase Novo's Oral Wegovy Head Start

Lilly's oral GLP-1 secured an FDA national priority voucher, slashing review times to 1–2 months. Unlike Novo's pill, patients don't need to fast for 30 minutes post-dose. As a small molecule, it's cheaper to manufacture and easier to negotiate into formularies.

BioPharma Dive

Analysis

Disc Medicine's Bitopertin Faces FDA Delay Despite 'Game Changing' Potential

Deputy CMO Mallika Mundkur called bitopertin "potentially game changing" for erythropoietic protoporphyria, but the FDA requested additional efficacy analyses in December. Despite the delay, Wall Street analysts remain optimistic. The drug clearly addresses a large unmet need with no approved therapies.

BioPharma Dive, STAT News

Approval

Ascendis' TransCon CNP Threatens BioMarin's Achondroplasia Monopoly

TransCon CNP works similarly to Voxzogo but requires only weekly injections versus daily shots. European regulators revoked BioMarin's patent last year, and analysts see low odds for a successful U.S. patent challenge. Decision deadline: end of February.

BioPharma Dive

Market Opportunity

Rhythm Eyes $1B+ Market With Imcivree Expansion Into Hypothalamic Obesity

Rhythm's Imcivree helped patients lose 20 percentage points more body weight than placebo in hypothalamic obesity trials. The FDA called for additional analyses in October, delaying the March 20 decision. Analysts see the delay as a "minor speedbump" with at least 10,000 U.S. patients eligible.

BioPharma Dive

Gene Therapy
Rocket Pharma Seeks Redemption With Kresladi for Leukocyte Adhesion Deficiency

Approval by March 28 would grant a priority review voucher worth nine figures · William Blair estimates $294M peak sales · BioPharma Dive

Science / Immuno-Oncology

Review

PROTACs and Molecular Glues Push Into Novel Target Space — Degraders Move From Discovery to Clinical Reality

Targeted protein degradation is transitioning from a serendipitous discovery to a rational drug design strategy. PROTACs use bifunctional molecules to recruit E3 ubiquitin ligases and induce proteasomal degradation of target proteins, while molecular glues reshape E3 ligase surfaces to enable proximity-induced degradation. Recent advances in structural biology and computational modeling have accelerated rational degrader discovery. Dual degraders that combine PROTAC and molecular glue features are now in development, with compounds like BWA-6047 achieving potent degradation of AR, AR-V7, and GSPT1 simultaneously. The field is rapidly moving from "undruggable" to "yet-to-be-drugged" targets.

Nature Reviews Drug Discovery, AACR Journals, ScienceDirect

Landmark Study

Bispecific T Cell Engagers in Autoimmune Disease — Blinatumomab and Teclistamab Show Efficacy

Researchers repurposed cancer immunotherapies for treatment-refractory autoimmune diseases with promising results. Bispecific antibodies redirect immune effector cells toward disease-causing targets, eliciting coordinated responses without genetic modification of patient cells.

Nature MedicineOncoImmunology

Analysis

CAR-T vs. Bispecifics — Decision Framework for Relapsed/Refractory Myeloma

New data from real-world cohorts show bispecific antibodies as bridging therapy compare favorably to chemotherapy before BCMA CAR-T. Earlier-line CAR-T yields superior outcomes, but bispecifics offer easier administration and no manufacturing delays. Sequencing strategies remain a key clinical question.

Blood Cancer DiscoveryOncLive, CancerNetwork

Study

CAR-T Cell Therapy Advances for Solid Tumors — New Antigen Targets Emerge

Researchers developed bispecific and split CAR (BissCAR) targeting CD13 and TIM3 using nanobodies. A2B694 showed expansion and tumor infiltration in ovarian, pancreatic, and non-small cell lung cancer without dose-limiting CRS or neurotoxicity. DLL3-targeted CAR-T therapy demonstrated dose-dependent activity in SCLC.

Signal TransductionPMC, Nature

Data

Bispecific Antibodies as Bridging Therapy Before CAR-T Shows Favorable Outcomes

In real-world cohorts, bridging with bispecific T cell-engaging antibodies compared favorably to chemotherapy, anti-CD38, and anti-SLAMF7 antibody-based regimens before BCMA CAR-T cell therapy. The approach maintains disease control without compromising subsequent CAR-T efficacy.

Blood Cancer DiscoveryAACR Journals

AI & Technology

Breaking

OpenAI Makes London Its Largest Research Hub Outside the U.S. — Direct Challenge to Google DeepMind

OpenAI announced plans to expand its London office into its biggest research hub outside San Francisco, scooping up talent from British universities and putting the company in direct competition with Google DeepMind for top researchers. The London team will "own" aspects of model development relating to safety, reliability, and performance evaluation while continuing to work on Codex and GPT-5.2. Mark Chen, OpenAI's chief research officer, cited the UK's world-class talent and leading scientific institutions as ideal for delivering safe, useful AI that benefits everyone. The move coincides with the UK's push to scale data center and power infrastructure to meet AI compute demands.

WIRED, Reuters, Digit

Analysis

London Becomes AI Talent Battleground — DeepMind vs. OpenAI

Google DeepMind, led by Demis Hassabis, has long-standing partnerships with Oxford and Cambridge, sponsoring professorships and funding research. OpenAI's expansion creates a "flywheel effect"—early-career hires may eventually start new labs in the UK, generating second-order impacts beyond initial headcount.

WIRED

Policy

UK Minister Calls OpenAI Expansion 'Huge Vote of Confidence' in AI Leadership

Science and Technology Secretary Liz Kendall described the announcement as validation of the UK's position at the cutting edge of AI research. The UK government is pushing AI Growth Zones to attract investment and scale infrastructure for compute-intensive workloads.

Reuters, IT Pro

Product
OpenAI Developing AI Devices Including Smart Speaker Priced $200–$300

First device unlikely to ship until February 2027 at earliest · The Information

Data
AI Updates Today: Reasoning Models Trade Speed for Accuracy

OpenAI o1 and DeepSeek-R1 leading reasoning trend · Multimodal capabilities now standard in frontier models · LLM Stats

NBA & Fantasy Basketball

Waiver Wire

Fantasy Basketball Week 19 Pickups — GG Jackson, Dylan Harper, and Scoot Henderson Lead Breakout Performances

As the fantasy playoffs approach, injury-driven opportunities are creating waiver wire gold. GG Jackson II posted 28 points and 9 rebounds in just 26 minutes against Miami, averaging 15 points, 5.6 rebounds, and 1.6 combined steals/blocks over his last 12 games on 53% shooting. Dylan Harper ran his double-digit scoring streak to five games with improved efficiency—62% from the field over his last nine games in a high-usage sixth-man role for San Antonio. Scoot Henderson returned from a torn hamstring, averaging 13.4 points and 5 assists in 20.2 minutes, with his minutes restriction now lifted. Cameron Johnson is thriving in Denver's injury-depleted frontcourt, averaging 16.5 points, 4 rebounds, and 3.5 assists since the All-Star break.

RotoWire, FantasyPros, RotoWire

Top Adds

Nolan Traore and Dylan Harper — Rookie Backcourt Duo Delivering Fantasy Value

Brooklyn's Nolan Traore has posted 15.7 points, 6.7 assists, and 1.2 steals on 51.5% shooting over his last six games as a starter. Harper's efficiency surge and locked-in role make him a must-add with four San Antonio games this week.

RotoWire

Deep League

Jarace Walker Breakout February — 16.9 Points, 8 Rebounds in Development Mode

With Indiana holding the worst win percentage in the East, the Pacers have shifted focus to development. Walker is averaging 16.9 points, 8 rebounds, 3.4 assists, and 1.1 steals in 29.3 minutes across seven February games. Pascal Siakam's frequent absences open consistent minutes.

FantasyPros

Week 19 Schedule

Avoid Clippers and Suns — Only Two Games Each This Week

Fourteen teams play four games this week, including Dallas, Memphis, Milwaukee, New Orleans, and Portland. Lakers, Pelicans, and Trail Blazers offer coveted Saturday-Sunday back-to-backs to close the scoring period.

RotoWire

Streaming

Maxime Raynaud Owns Sacramento's Center Role With Sabonis Out for Season

Following Domantas Sabonis' season-ending knee surgery, rookie Maxime Raynaud has averaged 14.5 points, 10.2 rebounds, 1.8 assists, and 1.2 steals in 30 minutes per game as a starter. The Kings' focus on development ensures consistent minutes rest-of-season.

FantasyPros

Trade Deadline
Post-Deadline Recap — 27 of 30 Teams Made Deals, Giannis Stayed Put

Anthony Davis to Wizards, Ivica Zubac to Pacers, Ayo Dosunmu to Wolves · Buyout market heating up · NBA.com, Yahoo Sports

Waiver Wire
Jay Huff and Day'Ron Sharpe — Centers Offering Blocks and Threes

Huff posted 22 points, 5 threes in 16 minutes · Sharpe drawing starts with Nicolas Claxton sidelined · RotoWire

Kids · Vienna

Event

Kinderaktionstag im Mumok — Freier Eintritt, Rätselrallye, Disco Drawing

Sonntag, 1. März, 10:00 Uhr — Kinder ab 3 Jahren werden zu Museumschefs. Umfangreiches Programm: Rätselrallye, Disco Drawing, offenes Atelier, Malen mit Licht, Bilderbuchkino. Zum Abschluss bastelt ein Ballonkünstler jedem Kind einen eigenen Luftballon. Freier Eintritt für Kinder und zwei Begleitpersonen.

Mumok, FALTER Kinder

Event

Science Busters for Kids — Wissenschaft zum Krachen, Brennen, Stinken

Sonntag, 1. März, 14:00 Uhr im Orpheum — Martin Puntigam, Helmut Jungwirth und Peter Weinberger erklären Kindern, was Wissenschaft kann: Impfstoffe entwickeln, auf den Mars fliegen, spektakuläre Experimente. "Wer nichts weiß, muss alles glauben" — ab 9 Jahren.

Orpheum, FALTER Kinder

Outdoor

Familienführung im Botanischen Garten — Überlebenskünstler der Pflanzenwelt

Sonntag, 1. März, 15:00 Uhr — Eine versteckte Oase im 3. Bezirk. 8 Hektar mit einzigartiger Pflanzensammlung. Diese Woche: Überlebenskünstler der Pflanzenwelt. Ab 5 Jahren geeignet. Anmeldung erforderlich unter www.booking.univie.ac.at.

Botanischer Garten, FALTER Kinder

Event

Sevi-Disco: Superheld:innen — Tanzen für Kinder 0–7 Jahre

Sonntag, 1. März, 10:00 Uhr — Kinderfreunde Indoor-Spielplatz Seversaal. Motto: Superheld:innen — gerne verkleidet kommen! Tickets vorab online kaufen empfohlen.

Seversaal, FALTER Kinder

Save the Date
Kindersachenmarkt & Kids Flohmarkt am Samstag, 28. Februar

Unterkirche Wien 10:00 Uhr · Nachbarschaftszentrum 7, 09:00 Uhr · Kleidung, Spielsachen, Bücher für 0–14 Jahre · FALTER Kinder

Film
Kino für die Kleinsten: Laut und leise — 6 Kurzfilme ab 3 Jahren

Filmmuseum · Sichtbare Töne, lautlose Straßenbahnen, singende Rüssel · Mit Filmvermittler · Österreichisches Filmmuseum